Meeting
2024 ASCO Genitourinary Cancers Symposium
Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis.
Authors
Syed Arsalan Ahmed Naqvi
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
Syed Arsalan Ahmed Naqvi , Irbaz Bin Riaz , Kaneez Zahra Rubab Khakwani , Arifa Bibi , Jack R. Andrews , Daniel S Childs , Praful Ravi , Jacob Orme , Parminder Singh , Christopher Sweeney , Alan Haruo Bryce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 171)
DOI
10.1200/JCO.2024.42.4_suppl.171
Abstract #
171
Poster Bd #
G21
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comparative effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: A parametric survival network meta-analysis of randomized controlled trials.
First Author: Lin Wang
Poster
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
First Author: Irbaz Bin Riaz
Poster
2024 ASCO Genitourinary Cancers Symposium
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
First Author: Benjamin L. Maughan
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer